Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2019 · 10-Q
Revenue$884.00K$884.00K−99.3% vs Q1 2018 Net Income-$32.23M-$32.23MN/M vs Q1 2018 EPS Diluted-$0.89-$0.89N/M vs Q1 2018 Operating Income-$35,906,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$31,752,000N/M Margins · derivedOperating margin-4061.8%−4138.8 pt vs Q1 2018
Net margin-3645.7%−3724.4 pt vs Q1 2018
ended Mar 31, 2019 · filed May 7, 2019 · 37 d after period end